Skip to main content
Top
Published in: Antimicrobial Resistance & Infection Control 1/2015

Open Access 01-12-2015 | Research

The costs of nosocomial resistant gram negative intensive care unit infections among patients with the systemic inflammatory response syndrome- a propensity matched case control study

Authors: Anupama Vasudevan, Babar Irfan Memon, Amartya Mukhopadhyay, Jialiang Li, Paul Ananth Tambyah

Published in: Antimicrobial Resistance & Infection Control | Issue 1/2015

Login to get access

Abstract

Background

Infections due to multi-drug resistant gram negative bacilli (RGNB) in critically ill patients have been reported to be associated with increased morbidity and costs and only a few studies have been done in Asia. We examined the financial impact of nosocomial RGNB infections among critically ill patients in Singapore.

Methods

A nested case control study was done for patients at medical and surgical ICUs of a tertiary university hospital (August 2007-December 2011) matched by propensity scores. Two groups of propensity-matched controls were selected for each case patient with nosocomial drug resistant gram negative infection: at-risk patients with no gram negative infection or colonization (Control A) and patients with ICU acquired susceptible gram negative infection (SGNB) (Control B). The costs of the hospital stay, laboratory tests and antibiotics prescribed as well as length of stay were compared using the Wilcoxon matched-pairs signed rank test.

Results

Of the 1539 patients included in the analysis, 76 and 65 patients had ICU acquired RGNB and SGNB infection respectively. The median(range) total hospital bill per day for patients with RGNB infection was 1.5 times higher than at-risk patients without GNB infection [Singapore dollars 2637.8 (458.7-20610.3) vs. 1757.4 (179.9-6107.4), p0.0001]. The same trend was observed when compared with SGNB infected patients. The median costs per day of antibiotics and laboratory investigations were also found to be significantly higher for patients with RGNB infection. The length of stay post infection was not found to be different between those infected with RGNB and SGNB.

Conclusion

The economic burden of RGNB infections to the patients and the hospital is considerable. Efforts need to be taken to prevent their occurrence by cost effective infection control practices.
Literature
1.
go back to reference Donowitz LG, Wenzel RP, Hoyt JW. High risk of hospital-acquired infection in the ICU patient. Crit Care Med. 1982;10:355–7.PubMedCrossRef Donowitz LG, Wenzel RP, Hoyt JW. High risk of hospital-acquired infection in the ICU patient. Crit Care Med. 1982;10:355–7.PubMedCrossRef
3.
go back to reference Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the infectious diseases society of America. Clin Infect Dis. 2009;48:1–12.PubMedCrossRef Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the infectious diseases society of America. Clin Infect Dis. 2009;48:1–12.PubMedCrossRef
4.
go back to reference Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41:848–54.PubMedCrossRef Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41:848–54.PubMedCrossRef
5.
go back to reference Van Duijn PJ, Dautzenberg MJD, Oostdijk EAN. Recent trends in antibiotic resistance in European ICUs. Curr Opin Crit Care. 2011;17(6):658–65.PubMedCrossRef Van Duijn PJ, Dautzenberg MJD, Oostdijk EAN. Recent trends in antibiotic resistance in European ICUs. Curr Opin Crit Care. 2011;17(6):658–65.PubMedCrossRef
6.
go back to reference Clark NM, Patterson J, Lynch JP. Antimicrobial resistance among gram-negative organisms in the intensive care unit. Curr Opin Crit Care. 2003;9:413–23.PubMedCrossRef Clark NM, Patterson J, Lynch JP. Antimicrobial resistance among gram-negative organisms in the intensive care unit. Curr Opin Crit Care. 2003;9:413–23.PubMedCrossRef
7.
go back to reference Hsu L-Y, Tan T-Y, Jureen R, Koh T-H, Krishnan P, Tzer-Pin Lin R, et al. Antimicrobial drug resistance in Singapore hospitals. Emerg Infect Dis. 2007;13:1944–7.PubMedCentralPubMedCrossRef Hsu L-Y, Tan T-Y, Jureen R, Koh T-H, Krishnan P, Tzer-Pin Lin R, et al. Antimicrobial drug resistance in Singapore hospitals. Emerg Infect Dis. 2007;13:1944–7.PubMedCentralPubMedCrossRef
8.
9.
go back to reference Neidell MJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, et al. Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. Clin Infect Dis. 2012;55:807–15.PubMedCentralPubMedCrossRef Neidell MJ, Cohen B, Furuya Y, Hill J, Jeon CY, Glied S, et al. Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. Clin Infect Dis. 2012;55:807–15.PubMedCentralPubMedCrossRef
10.
go back to reference Webb M, Riley LW, Roberts RB. Cost of hospitalization for and risk factors associated with vancomycin-resistant Enterococcus faecium infection and colonization. Clin Infect Dis. 2001;33:445–52.PubMedCrossRef Webb M, Riley LW, Roberts RB. Cost of hospitalization for and risk factors associated with vancomycin-resistant Enterococcus faecium infection and colonization. Clin Infect Dis. 2001;33:445–52.PubMedCrossRef
11.
go back to reference Evans HL, Lefrak SN, Lyman J, Smith RL, Chong TW, McElearney ST, et al. Cost of Gram-negative resistance. Crit Care Med. 2007;35:89–95.PubMedCrossRef Evans HL, Lefrak SN, Lyman J, Smith RL, Chong TW, McElearney ST, et al. Cost of Gram-negative resistance. Crit Care Med. 2007;35:89–95.PubMedCrossRef
12.
go back to reference Shorr AF. Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med. 2009;37:1463–9.PubMedCrossRef Shorr AF. Review of studies of the impact on Gram-negative bacterial resistance on outcomes in the intensive care unit. Crit Care Med. 2009;37:1463–9.PubMedCrossRef
13.
go back to reference Rosenbaum PR. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41–55.CrossRef Rosenbaum PR. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41–55.CrossRef
14.
go back to reference D’Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265–81.PubMedCrossRef D’Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265–81.PubMedCrossRef
15.
go back to reference Vasudevan A, Chuang L, Jialiang L, Mukhopadhyay A, Goh EY-Y, Tambyah PA. Inappropriate empirical antimicrobial therapy for multidrug-resistant organisms in critically ill patients with pneumonia is not an independent risk factor for mortality: results of a prospective observational study of 758 patients. J Glob Antimicrob Resist. 2013;1:123–30.CrossRef Vasudevan A, Chuang L, Jialiang L, Mukhopadhyay A, Goh EY-Y, Tambyah PA. Inappropriate empirical antimicrobial therapy for multidrug-resistant organisms in critically ill patients with pneumonia is not an independent risk factor for mortality: results of a prospective observational study of 758 patients. J Glob Antimicrob Resist. 2013;1:123–30.CrossRef
16.
go back to reference Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–81.PubMedCrossRef Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–81.PubMedCrossRef
17.
go back to reference Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128–40.PubMedCrossRef Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128–40.PubMedCrossRef
18.
go back to reference Vasudevan A, Mukhopadhyay A, Li J, Yuen E, Tambyah P. A prediction tool for nosocomial multi-drug resistant gram-negative bacilli infections in critically ill patients - prospective observational study. BMC Infect Dis. 2014;14:615.PubMedCentralPubMedCrossRef Vasudevan A, Mukhopadhyay A, Li J, Yuen E, Tambyah P. A prediction tool for nosocomial multi-drug resistant gram-negative bacilli infections in critically ill patients - prospective observational study. BMC Infect Dis. 2014;14:615.PubMedCentralPubMedCrossRef
19.
go back to reference Cooper LM, Linde-Zwirble WT. Medicare intensive care unit use: analysis of incidence, cost, and payment. Crit Care Med. 2004;32:2247–53.PubMed Cooper LM, Linde-Zwirble WT. Medicare intensive care unit use: analysis of incidence, cost, and payment. Crit Care Med. 2004;32:2247–53.PubMed
20.
go back to reference Daxboeck F, Budic T, Assadian O, Reich M, Koller W. Economic burden associated with multi-resistant Gram-negative organisms compared with that for methicillin-resistant Staphylococcus aureus in a university teaching hospital. J Hosp Infect. 2006;62:214–8.PubMedCrossRef Daxboeck F, Budic T, Assadian O, Reich M, Koller W. Economic burden associated with multi-resistant Gram-negative organisms compared with that for methicillin-resistant Staphylococcus aureus in a university teaching hospital. J Hosp Infect. 2006;62:214–8.PubMedCrossRef
21.
go back to reference Horcajada JP, Belvis F, Castells X, Grau S, Riu M, Morales E, et al. Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. BMC Health Serv Res. 2012;12:122.PubMedCentralPubMedCrossRef Horcajada JP, Belvis F, Castells X, Grau S, Riu M, Morales E, et al. Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. BMC Health Serv Res. 2012;12:122.PubMedCentralPubMedCrossRef
22.
go back to reference Lee N-Y, Lee H-C, Ko N-Y, Chang C-M, Shih H-I, Wu C-J, et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol. 2007;28:713–9.PubMedCrossRef Lee N-Y, Lee H-C, Ko N-Y, Chang C-M, Shih H-I, Wu C-J, et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol. 2007;28:713–9.PubMedCrossRef
23.
go back to reference Wilson SJ, Knipe CJ, Zieger MJ, Gabehart KM, Goodman JE, Volk HM, et al. Direct costs of multidrug-resistant Acinetobacter baumannii in the burn unit of a public teaching hospital. Am J Infect Control. 2004;32:342–4.PubMedCrossRef Wilson SJ, Knipe CJ, Zieger MJ, Gabehart KM, Goodman JE, Volk HM, et al. Direct costs of multidrug-resistant Acinetobacter baumannii in the burn unit of a public teaching hospital. Am J Infect Control. 2004;32:342–4.PubMedCrossRef
24.
go back to reference Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001;32:1162–71.PubMedCrossRef Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001;32:1162–71.PubMedCrossRef
25.
go back to reference Ng E, Earnest A, Lye DC, Ling ML, Ding Y, Hsu LY. The excess financial burden of multidrug resistance in severe gram-negative infections in Singaporean hospitals. Ann Acad Med Singapore. 2012;41:189–93.PubMed Ng E, Earnest A, Lye DC, Ling ML, Ding Y, Hsu LY. The excess financial burden of multidrug resistance in severe gram-negative infections in Singaporean hospitals. Ann Acad Med Singapore. 2012;41:189–93.PubMed
26.
go back to reference Piddock LJ. Antibiotic action: helping deliver action plans and strategies. Lancet Infect Dis. 2013;13:1009–11.PubMedCrossRef Piddock LJ. Antibiotic action: helping deliver action plans and strategies. Lancet Infect Dis. 2013;13:1009–11.PubMedCrossRef
31.
go back to reference Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA. 2000;284:1954–61.PubMedCrossRef Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA. 2000;284:1954–61.PubMedCrossRef
32.
go back to reference Kollef MH, Golan Y, Micek ST, Shorr AF, Restrepo MI. Appraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections--proceedings and data from the Gram-Negative Resistance Summit. Clin Infect Dis. 2011;53 Suppl 2:S33–55. quiz S56–8.PubMedCentralPubMedCrossRef Kollef MH, Golan Y, Micek ST, Shorr AF, Restrepo MI. Appraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections--proceedings and data from the Gram-Negative Resistance Summit. Clin Infect Dis. 2011;53 Suppl 2:S33–55. quiz S56–8.PubMedCentralPubMedCrossRef
33.
go back to reference Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol. 2006;27:1226–32.PubMedCrossRef Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol. 2006;27:1226–32.PubMedCrossRef
34.
go back to reference Roberts RR, Hota B, Ahmad I, Scott RD, Foster SD, Abbasi F, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis. 2009;49:1175–84.PubMedCrossRef Roberts RR, Hota B, Ahmad I, Scott RD, Foster SD, Abbasi F, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis. 2009;49:1175–84.PubMedCrossRef
Metadata
Title
The costs of nosocomial resistant gram negative intensive care unit infections among patients with the systemic inflammatory response syndrome- a propensity matched case control study
Authors
Anupama Vasudevan
Babar Irfan Memon
Amartya Mukhopadhyay
Jialiang Li
Paul Ananth Tambyah
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Antimicrobial Resistance & Infection Control / Issue 1/2015
Electronic ISSN: 2047-2994
DOI
https://doi.org/10.1186/s13756-015-0045-8

Other articles of this Issue 1/2015

Antimicrobial Resistance & Infection Control 1/2015 Go to the issue